NCT07547007 Benefits of a 6-month, Individualized, Hybrid, "Real-life" Adapted Physical Activity Program on the Quality of Life of Patients Treated for Multiple Myeloma
| NCT ID | NCT07547007 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Metropole Savoie |
| Condition | Multiple Myeloma (MM) |
| Study Type | INTERVENTIONAL |
| Enrollment | 86 participants |
| Start Date | 2026-01-22 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 86 participants in total. It began in 2026-01-22 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate the effect of a long-term, individualized, hybrid adapted physical activity program on the quality of life of patients with multiple myeloma. The main question it aims to answer are : Does this logn term, individualized and hybrid adapted physical activity program improve quality of life in multiple myeloma patient ? What are the effects of this program on effort tolerance, pain, muscular mass, osteolytic lesions, tolerance to treatment, response to treatment? If there is a comparison group: Researchers will compare \[arm information\] to see if \[insert effects\]. Participants will be randomised in 2 groups. * control group: patients will receive only advices about physical activities benefit * interventional group: This group will be offered a program of adapted physical activities mixing sessions at home (remote) and sessions at the hospital (in person).
Eligibility Criteria
Inclusion Criteria: * newly diagnosed or relapse multiple myeloma, \> 60 yo, not eligible to transplant * 1st to 4th line of treatment initiated during the last 3 months * receiving a systemic treatment that involved visit to the hospital at least twice a month durig the first 3 months and at least once a month the next 3 months Exclusion Criteria: * severe cardiac amyloidosis * absolute contraindication to physical activity * inability to comply with the protocol requirements * not french speaker * patient under guardianship or curatorship * pregnant or lactating women
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07547007 clinical trial?
This trial is open to participants of all sexes, aged 61 Years or older, studying Multiple Myeloma (MM). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07547007 currently recruiting?
Yes, NCT07547007 is actively recruiting participants. Contact the research team at charlene.dupre@ch-metropole-savoie.fr for enrollment information.
Where is the NCT07547007 trial being conducted?
This trial is being conducted at Annecy, France, Chambéry, France.
Who is sponsoring the NCT07547007 clinical trial?
NCT07547007 is sponsored by Centre Hospitalier Metropole Savoie. The trial plans to enroll 86 participants.